Cumyl-BC-HpMeGaClone-221 (Cumyl-BC
.2.1pMeGaClone, SGT-271) is a
gamma-carboline derivative which is a
synthetic cannabinoid
Synthetic cannabinoids, or neocannabinoids, are a class of designer drug molecules that Binding affinity, bind to the same receptors to which cannabinoids (Tetrahydrocannabinol, THC, Cannabidiol, CBD and many others) in cannabis plants attach. Th ...
that has been sold as a
designer drug
A designer drug is a structural or functional analog of a controlled substance that has been designed to mimic the pharmacological effects of the original drug, while avoiding classification as illegal and/or detection in standard drug tests. ...
. It was first identified in Germany in September 2020.
See also
*
CUMYL-CB-MEGACLONE
*
CUMYL-CH-MEGACLONE
CUMYL-CH-MEGACLONE (CUMYL-CHMGACLONE, SGT-270) is a gamma-carboline based synthetic cannabinoid receptor agonist that has been sold as a designer drug, first being identified in Hungary in December 2018.
See also
* 5F-CUMYL-PEGACLONE
* CUMYL ...
*
CUMYL-PEGACLONE
CUMYL-PEGACLONE (SGT-151) is a gamma-carboline based synthetic cannabinoid that has been sold as a designer drug. The gamma-carboline core structure seen in CUMYL-PEGACLONE had not previously been encountered in a designer cannabinoid, though it ...
*
CUMYL-NBMINACA
CUMYL-NBMINACA (SGT-152, Cumyl-BC .2.1pMINACA) is a synthetic cannabinoid compound first reported in a 2013 patent, but not identified as a designer drug until 2021, being identified by a forensic laboratory in Germany in February 2021.
See also ...
References
Cannabinoids
Designer drugs
Gamma-Carbolines
Nitrogen heterocycles
Heterocyclic compounds with 2 rings
{{cannabinoid-stub